Guangzhou Zhiyao Biotechnology

Guangzhou Zhiyao Biotechnology is a China-based biotechnology company that leverages artificial intelligence to accelerate the discovery and development of novel small molecule therapeutics. Founded in 2021, the company utilizes its proprietary AI-driven drug discovery (AIDD) platform to target high-value and difficult-to-drug pathways in oncology. Its lead candidate, ZY022, is a selective USP1 inhibitor that has received IND approval and entered clinical trials for the treatment of advanced solid tumors, particularly those with DNA damage repair deficiencies. The company's pipeline also includes programs targeting KRAS G12D and HPK1, reflecting a focus on precision medicine and immunotherapy. Backed by leading investors like GL Ventures and Source Code Capital, Guangzhou Zhiyao Biotechnology aims to integrate computational power with biological insights to deliver transformative treatments for cancer patients.